Juha Punnonen, M.D., Ph.D. Joins Hinge Bio As Chief Development Officer
05/31/23, 3:01 AM
Location
burlingame
Industry
therapeutics
health care
biotechnology
Position
chief development officer
Hinge Bio, Inc., a privately-held biotechnology company, today announced that Juha Punnonen, M.D., Ph.D. has joined the company as Chief Development Officer. Dr
Company Info
Location
863 mitten road, suite 100l
burlingame, california, united states
Additional Info
Hinge Bio is a privately held biotechnology company leveraging its powerful GEM-DIMERâ„¢ platform to develop therapeutics that address the problems of inadequate efficacy, resistance and side effects. The GEM-DIMER platform creates multivalent, multispecific antibody-based therapeutics that bind their targets in a novel manner allowing for dramatically enhanced biological activity and unique functionality. The GEM-DIMER technology was invented by Hinge Bio's Chief Scientific Officer, Daniel Capon, Ph.D., who previously was the first to clone and express recombinant Factor VIII (Genentech) and invented Fc-fusion proteins (Genentech) as well as chimeric antigen receptors for T cell therapy/CAR-T (Cell Genesys). Dr. Capon also holds patents on the XenoMouse for the production of fully human antibodies (Abgenix) and the PhenoSense drug susceptibility and resistance test (Monogram Biosciences/LabCorp). Learn more at www.hingebio.com.